ecancer
ecancer is a UK charity which provides accessible, high-quality educational content, free to the global oncology community. Our mission is to raise the standards of care for cancer patients across the world through education.
ASCO 2022
ecancer
Lecture Summary - ASCO 2022 Sacituzumab Govitecan Provides Clinically Meaningful PFS Benefit for HR+/HER2- mBC
FEATURING
Hope Rugo
- 5 views
- June 29, 2022
ecancer
ASCO 2022: ASCO and WHO to Collaborate on Quality Indicators for Cancer Facilities
FEATURING
André Ilbawi
- 5 views
- June 27, 2022
ecancer
ASCO 2022 on the rEECur Trial: High-Dose Ifosfamide as a SoC for Recurrent and Primary Refractory Ewing Sarcoma
FEATURING
Martin Mccabe
- 20 views
- June 24, 2022
ecancer
ASCO 2022: Dabrafenib + Trametinib Significantly Increases Overall Response Rate in Pediatric Low-Grade Gliomas
FEATURING
Eric Bouffet
- 61 views
- June 24, 2022
- 1
ecancer
ASCO 2022 Panel Discussion on Current Strategies and Trials on Bladder Preservation
- 127 views
- June 23, 2022
ecancer
ASCO 2022: Single-Agent PD-1 Blockade as Curative-Intent Treatment in dMMR Locally Advanced Rectal Cancer
FEATURING
Andrea Cercek
- 58 views
- June 23, 2022
ecancer
ASCO 2022 on a Phase II S1800A Trial: Ramucirumab + Pembrolizumab Improves OS in Advanced NSCLC
FEATURING
Roy Herbst
- 67 views
- June 23, 2022
ecancer
ASCO 2022: N-803 + BCG Combination Shows Promising Results in BCG-Unresponsive NMIBC
FEATURING
Karim Chamie
- 82 views
- June 23, 2022
ecancer
ASCO 2022 on the Adjuvant Endocrine Therapy for ER+/HER2- Breast Cancer
FEATURING
Etienne Brain
- 113 views
- June 23, 2022
ecancer
ASCO 2022 Sacituzumab Govitecan Provides Clinically Meaningful PFS Benefit for HR+/HER2- mBC
FEATURING
Hope Rugo
- 786 views
- June 23, 2022
- 5
ecancer
Updated Data From the Phase 1/2 MajesTEC-1 Study: Evaluating Teclistamab in R/R MM
FEATURING
Ajay Nooka
- 1,163 views
- June 23, 2022
- 2
ecancer
ASCO 2022 Phase III EVEREST Study Updates: Everolimus After Surgery Can Improve Outcomes in Those With High-Risk RCC
FEATURING
Christopher Ryan
- 59 views
- June 21, 2022
ecancer
ASCO 2022 ctDNA Analysis Can Help Identify the Need for Adjuvant Therapy in Stage II Colon Cancer
FEATURING
Jeanne Tie
- 95 views
- June 21, 2022
ecancer
ASCO 2022 Panitumumab + mFOLFOX6 Improves OS for RAS Wild-Type Left-Sided mCRC
FEATURING
Takayuki Yoshino
- 65 views
- June 20, 2022
ecancer
ASCO 2022 Momelotinib Superior to Danazol in Symptomatic and Anaemic MF Pts Previously Treated With a JAKi
FEATURING
Ruben Mesa
- 131 views
- June 17, 2022
- 1
ecancer
ASCO 2022 Biomarker Analysis of the NeoALTTO Trial Provides Oncofertility Insight for Younger Breast Cancer Pts
FEATURING
Matteo Lambertini
- 2 views
- June 17, 2022
ecancer
ASCO 2022 DESTINY-Breast04: Trastuzumab Deruxtecan vs. Treatment of Physician’s Choice in Pts With HER2-Low Unresectable/Metastatic BC
FEATURING
Shanu Modi
- 211 views
- June 17, 2022
- 1
ecancer
ASCO 2022 DESTINY-Breast04: Trastuzumab Deruxtecan Doubles PFS in MBC With Low HER2 Expression
FEATURING
Shanu Modi
- 30 views
- June 17, 2022